Table 5 Combined analysis for XPC, XPD and XRCC3 polymorphisms and lung cancer risk estimates
Genotype 1 | Genotype 2 | Cases n(%) | Controls n(%) | Adjusteda OR [95% CI] | P | P interaction |
|---|---|---|---|---|---|---|
XPC PAT | XPD Lys751Gln | Â | Â | Â | Â | Â |
-/- | Lys/Lys | 72 (13.9) | 84 (15.8) | 1.00 (reference) | Â | Â |
+/+ | Lys/Lys | 36 (7.0) | 38 (7.1) | 1.10 [0.59–2.06] | 0.971 |  |
+/+ | Lys/Gln | 49 (9.5) | 37 (6.9) | 1.63 [0.89–2.98] | 0.111 |  |
+/+ | Gln/Gln | 16 (3.1) | 9 (1.7) | 2.25 [0.83–6.13] | 0.202 | 0.202 |
XPC PAT | XRCC3 Thr241Met | Â | Â | Â | Â | Â |
-/- | Thr/Thr | 49 (12.2) | 60 (13.8) | 1.00 (reference) | Â | Â |
+/+ | Thr/Thr | 36 (8.9) | 31 (7.1) | 1.22 [0.61–2.43] | 0.578 |  |
+/+ | Thr/Met | 34 (8.4) | 27 (6.2) | 1.41 [0.68–2.92] | 0.351 |  |
+/+ | Met/Met | 12 (3.0) | 6 (1.4) | 3.06 [0.91–10.30] | 0.071 | 0.174 |
XPD Lys751Gln | XRCC3 Thr241Met | Â | Â | Â | Â | Â |
Lys/Lys | Thr/Thr | 83 (20.6) | 89 (20.5) | 1.00 (reference) | Â | Â |
Gln/Gln | Thr/Thr | 17 (4.2) | 17 (3.9) | 0.98 [0.41–2.35] | 0.968 |  |
Gln/Gln | Thr/Met | 20 (5.0) | 18 (4.1) | 1.59 [0.70–3.59] | 0.264 |  |
Gln/Gln | Met/Met | 10 (2.5) | 5 (1.2) | 2.66 [0.74–9.62] | 0.135 | 0.261 |